Renaissance Technologies LLC grew its stake in shares of Haemonetics Co. (NYSE:HAE) by 11.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 977,100 shares of the medical instruments supplier’s stock after buying an additional 100,893 shares during the quarter. Renaissance Technologies LLC owned 1.83% of Haemonetics worth $56,750,000 at the end of the most recent quarter.
Several other institutional investors also recently bought and sold shares of the company. Koch Industries Inc. raised its position in shares of Haemonetics by 20.2% during the 4th quarter. Koch Industries Inc. now owns 8,282 shares of the medical instruments supplier’s stock valued at $481,000 after buying an additional 1,392 shares in the last quarter. Invictus RG raised its position in shares of Haemonetics by 809.9% during the 4th quarter. Invictus RG now owns 5,605 shares of the medical instruments supplier’s stock valued at $326,000 after buying an additional 4,989 shares in the last quarter. Bogle Investment Management L P DE raised its position in shares of Haemonetics by 681.2% during the 4th quarter. Bogle Investment Management L P DE now owns 215,757 shares of the medical instruments supplier’s stock valued at $12,531,000 after buying an additional 188,138 shares in the last quarter. WINTON GROUP Ltd purchased a new stake in shares of Haemonetics during the 4th quarter valued at $6,257,000. Finally, Lazard Asset Management LLC purchased a new stake in shares of Haemonetics during the 4th quarter valued at $274,000. Hedge funds and other institutional investors own 99.91% of the company’s stock.
In other Haemonetics news, Director Mark W. Kroll sold 7,118 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $63.00, for a total value of $448,434.00. Following the transaction, the director now owns 33,881 shares in the company, valued at $2,134,503. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michelle L. Basil sold 389 shares of the business’s stock in a transaction dated Tuesday, March 6th. The shares were sold at an average price of $72.23, for a total transaction of $28,097.47. The disclosure for this sale can be found here. Insiders sold 7,621 shares of company stock worth $484,766 in the last 90 days. Corporate insiders own 1.20% of the company’s stock.
Haemonetics Co. (HAE) opened at $74.41 on Wednesday. The company has a market cap of $3,949.77, a price-to-earnings ratio of 40.60, a P/E/G ratio of 3.66 and a beta of 0.92. Haemonetics Co. has a 52-week low of $38.43 and a 52-week high of $74.58. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.82 and a quick ratio of 1.33.
Haemonetics (NYSE:HAE) last issued its earnings results on Tuesday, February 6th. The medical instruments supplier reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.18. Haemonetics had a negative net margin of 1.94% and a positive return on equity of 12.39%. The company had revenue of $234.04 million for the quarter, compared to analysts’ expectations of $227.79 million. During the same quarter last year, the company earned $0.43 EPS. The firm’s revenue was up 2.7% compared to the same quarter last year. analysts forecast that Haemonetics Co. will post 1.86 earnings per share for the current year.
Haemonetics declared that its board has initiated a share repurchase plan on Tuesday, February 6th that permits the company to repurchase $260.00 million in outstanding shares. This repurchase authorization permits the medical instruments supplier to buy shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its shares are undervalued.
TRADEMARK VIOLATION WARNING: “Renaissance Technologies LLC Boosts Stake in Haemonetics Co. (HAE)” was originally published by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/03/14/renaissance-technologies-llc-boosts-stake-in-haemonetics-co-hae.html.
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.